Combined Immunotherapy and Conventional Chemotherapy in Cancer Patients

Publish Year: 1397
نوع سند: مقاله کنفرانسی
زبان: English
View: 433

نسخه کامل این Paper ارائه نشده است و در دسترس نمی باشد

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

NSCMRMED03_088

تاریخ نمایه سازی: 30 دی 1397

Abstract:

Despite promising success in immunotherapy of cancer patients, aconsiderable part of these patients does not reach to optimum responseto these agents such as PD-1 and PD-L1 inhibitors. Recent interest isto achieve the additive efficacy of immunotherapy in combinationwith conventional chemotherapy agents. The schedule and dosage ofchemotherapy agents like metronomic treatment can play as a gamechanger in this strategy. This integration of immunotherapy with standardcancer therapy can promote immunogenic cell death with a variousmechanism such as modulate the immune phenotype of residual tumor cells, minimize of the negative impact of tumor burden and up-regulationthe expression of tumor antigen.

Authors

Alireza Rezvani

Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran